Eli Lilly 2012 Annual Report Download - page 79
Download and view the complete annual report
Please find page 79 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69 -
70 -
71 -
72 -
73 -
74 -
75 -
76 -
77 -
78 -
79 -
80 -
81 -
82 -
83 -
84 -
85 -
86 -
87 -
88 -
89 -
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
 |
 |
67
Stock Option Program
Stock options were granted prior to 2007 to officers, management, and board members at exercise prices
equal to the fair market value of our stock price at the date of grant. Options fully vested 3 years from the
grant date and have a term of 10 years.
Stock option activity during the year ended December 31, 2012 is summarized below:
Shares of
Common Stock
Attributable to
Options
(in thousands)
Weighted-Average
Exercise
Price of Options
Weighted-Average
Remaining
Contractual Term
(in years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2012. . . . . . . . . 36,556 $ 66.22
Exercised. . . . . . . . . . . . . . . . . . . . . . . . . . . (50) 20.37
Forfeited or expired . . . . . . . . . . . . . . . . . . (9,274) 73.28
Outstanding at December 31, 2012. . . . . . 27,232 63.89 1.2 $ 0.4
Exercisable at December 31, 2012 . . . . . . 27,232 63.89 1.2 0.4
For options exercised during the years ended December 31, 2012, 2011, and 2010, the related intrinsic value,
cash received, and tax benefits were not material.
Note 10: Other Assets and Other Liabilities
Other receivables include tax receivables, receivables from our collaboration partners, interest receivable on
the interest rate swaps, and a variety of other items.
Prepaid expenses and other includes global prepaid operating expenses and deferred taxes (Note 13).
Sundry assets primarily include deferred tax assets (Note 13), the fair value of interest rate swaps, capitalized
computer software, and prepaid retirement plan outside the United States.
Other current liabilities include deferred income from our collaboration arrangements, other taxes payable,
the current portion of our estimated product return liabilities, and a variety of other items.
Other noncurrent liabilities include deferred income from our collaboration and out-licensing arrangements,
the long-term portion of our estimated product return liabilities, deferred tax liabilities (Note 13), product
litigation, and a variety of other items.